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 27 
Abstract: 28 
There is a growing interest in developing bioresponsive drug delivery systems to achieve 29 
greater control over drug release than can be achieved with the conventional diffusion 30 
controlled polymeric delivery systems. While a number of such systems have been 31 
studied for oral or parenteral delivery, little or no work has been done on bioresponsive 32 
delivery systems for inhalation. Using the raised elastase levels present at sites of lung 33 
inflammation as a proof-of-concept model, we endeavoured to develop a prototype of 34 
inhalable elastase sensitive microparticles (ESMs). Microparticles degradable by the 35 
enzyme elastase were formed by crosslinking the polymer alginate in the presence of an 36 
elastase substrate, elastin, using Ca+2 ions and subsequent spray drying. The 37 
bioresponsive release of a protein cargo in the presence of elastase demonstrated the 38 
enzyme-specific degradability of the particles. The microparticles showed favorable 39 
properties such as high drug encapsulation and good powder dispersibility. Potential 40 
polymer toxicity in the lungs was assessed by impinging the microparticles on Calu-3 cell 41 
monolayers and assessing changes in transepithelial permeability and induction of 42 
cytokine release. The microparticles displayed no toxic or immunogenic effects. With a 43 
manufacturing method that is amenable to scale-up, the ability to be aerosolised 44 
efficiently from a first-generation inhaler device, enzyme-specific degradability and lack of 45 
toxicity, the ESMs  show  significant  promise as  pulmonary  drug  carriers. 46 
Keywords: Elastin, Alginate, Pulmonary drug delivery47 
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1. Introduction 54 
Drug release from traditional polymeric drug delivery systems (DDS) occurs when the 55 
polymer degrades in the body via non-specific chemical reactions such as hydrolysis of 56 
ester linkages in the polymer. These DDS have many disadvantages such as inconsistent 57 
drug release kinetics, lack of response to physiological changes occuring in the body and 58 
significant inter and intra-patient variability[1]. To overcome these limitations, research in 59 
the past decade has focused on the development of bioresponsive polymers that can 60 
respond to various physiological stimuli in the local environment to release their drug 61 
payload. Enzyme-sensitive DDS are of growing interest. Certain disease processes e.g. 62 
cancer, infection and inflammation, are characterised by high levels of activity of specific 63 
extracellular and/or intracellular proteases. Bioresponsive DDS harnessing these increased 64 
enzyme levels to target drugs to the diseased site are being explored[2]. Enzyme-controlled 65 
drug release in tumors by tumor-associated proteases (e.g., plasmin) and in the gastro-66 
intestinal tract by digestive enzymes has been reported [3-4]. An advantage with enzymatic 67 
cleavage is that it breaks down polymers faster than the normal hydrolytic mechanism. This 68 
prevents accumulation of the carrier at the site of delivery. Secondly, drug release from 69 
such systems occurs only in the presence of the disease-specific enzyme and not at other 70 
sites. This allows spatial control of drug release (i.e, releasing drug only where it is 71 
required) to be achieved. 72 
Enzyme-responsive DDS can be particularly useful to achieve local drug delivery at sites of 73 
inflammation. Inflammation is an immune response that is characteristic of many disease 74 
states. It is implicated in wound healing and many diseases such as cancer, rheumatoid 75 
arthritis, diabetes, infection etc [5] . During this process, immune cells, especially 76 
neutrophils infiltrate the site of injury and secrete a number of proteases (e.g. neutrophil 77 
elastase (NE)) in an attempt to remove the harmful stimuli. Inflammatory lung conditions 78 
such as chronic bronchitis and emphysema show high levels of NE[6]. By developing an 79 
inhalable elastase-sensitive DDS, it could be possible to restrict drug release at sites of 80 
lung inflammation, thereby providing a combination of temporal and spatial control of drug 81 
delivery to the patient[5]. By delivering their therapeutic payload directly to the site of 82 
inflammation, such DDS not only provide enhanced targeting but also minimize drug 83 
4 
 
associated side-effects through a reduction of the dose that needs to be delivered. 84 
Inflammation being a common feature of many disease conditions, such systems can also 85 
potentially be used to target anti-inflammatory drugs to other sites in the body. 86 
In situations where the use of a single polymeric material does not satisfy all drug delivery 87 
requirements (e.g. resistance against rapid dissolution in aqueous media), a combination of 88 
two different polymers have been used to produce a new material that displays the 89 
combined advantages of the two individual polymers[7]. Such a system is termed an IPN 90 
(Inter-penetrating network). An IPN is a material which comprises two or more networks 91 
which are fully or partially interlaced on a molecular scale but not covalently bonded to 92 
each other and cannot be separated unless chemical bonds are broken. Enzymatically 93 
degradable IPNs consisting of a protein and a polysaccharide have been reported. For 94 
example, IPN hydrogels made of gelatin and dextran have been studied as materials for 95 
biodegradable implants and as carriers for drug delivery[8].  96 
Elastin is one of the primary substrates of NE. It is an extracellular matrix protein found in 97 
skin, blood vessels, and tissues of the lung. It imparts elasticity and flexibility to these 98 
tissues. Elastin-based biomaterials are being increasingly studied for tissue engineering 99 
and drug delivery applications[9]. Elastin particles having diameters between 200nm to 100 
10µm and containing fluorescently-labelled model drugs were prepared as potential drug 101 
delivery systems by a novel approach using lyophilisation. The particles underwent 102 
degradation in the presence of elastase to release their cargo[10]. No such delivery 103 
systems have been studied for treatment of lung diseases. In this study, we sought to 104 
determine whether DDS based on elastin could be used as inhalable drug carriers for 105 
potential treatment of inflammatory lung diseases. Bovine serum albumin was 106 
encapsulated within the particles as a model protein. 107 
2. Materials and methods 108 
2.1 Materials 109 
Bovine Serum Albumin-Fluorescein Isothiocyanate (BSA-FITC), Sodium fluorescein (Na-110 
Flu), low viscosity alginic acid sodium salt from Macrocystis pyrifera, and elastin, soluble 111 
from bovine neck ligament were purchased from Sigma Chemical Co. (St. Louis, MO, 112 
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USA). D-Mannitol (Mannidex®) was a gift from Cerestar, Belgium. Calu-3 cells were 113 
obtained from American Type Culture Collection, Rockville, MD, USA. Cell culture media 114 
and supplements were purchased from Gibco BRL, Paisley, Scotland. Tissue culture 115 
plastics were from Sarstedt AG & Co., Germany and Transwell clear polyester inserts 116 
(12mm diameter, pore size 0.4m) from Corning Costar, Corning, NY.  117 
2.2 Preparation of protein-loaded microparticles 118 
Alginate was dissolved in DI water at 0.3%w/v. Elastin and BSA-FITC were added to this 119 
solution (Elastin:alginate ratio = 1:6, BSA-FITC: polymer =1:100) and stirred to dissolve. 120 
The solution was homogenized at 6500 rpm for 10 minutes while 10ml of CaCl2 solution 121 
(10mM Ca+2) was added at a constant rate dropwise. The resulting mixture was spray dried 122 
using a laboratory Buchi 190 spray dryer (Buchi, Flawil, Switzerland). The following 123 
conditions were used: Inlet temperature: 170ºC, Outlet temperature: 56 ºC, Pump flow: 124 
22%, Aspirator: 75%. The recovered particles were stored in a desiccator at 4°C until 125 
further use.  126 
 127 
2.3 Protein loading 128 
To determine the encapsulation efficiency (%EE) of BSA-FITC, 10mg of microparticles 129 
were completely dissolved in 5ml of an aqueous solution of 0.1M sodium citrate by 130 
magnetic stirring for 4 hours[11]. The protein content was analysed by UV 131 
spectrophotometry at 495nm (Biochrom, UK).  132 
 133 
2.4 Particle characterisation 134 
Morphological assessment was performed using a Hitachi scanning electron microscope 135 
(Model S3500N) after mounting the preparations on studs and sputter–coating with gold 136 
(Polaron SC500 Gold Sputter Coater, Quotum technologies, Newhaven, UK). The particle 137 
size of the microparticles was determined by laser diffraction (Malvern Mastersizer 2000, 138 
Malvern Instruments Ltd, Malvern, UK) following suspension of the microparticles (25mg) 139 
in 5ml ethanol and bath sonication for one minute (320 W, Branson Ultrasonic, Danbury, 140 
CT). The density of the microparticles was determined as the tapped density using a tap 141 
density tester (Copley Scientific, Nottingham, UK)[12].  142 
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2.5 Determination of aerosolisation efficiency 143 
An Andersen Cascade Impactor (ACI) (Copley Ltd., Nottingham, UK) was used to 144 
determine the fine particle fraction (FPF) of the microparticles. To avoid particle bounce 145 
from the plates and re-entrainment in the flowing air, each plate of the impactor was coated 146 
with a solution of Tween 80 in acetone (5%w/v). Acetone was evaporated by placing the 147 
plates in an oven at 60°C for 5 minutes[13]. About 5mg of the blend was manually loaded 148 
into the Diskhaler® and aerosolised by drawing air at a flow rate of 60 lmin-1 for 4 seconds 149 
through the ACI. Five such doses were discharged into the apparatus. The apparatus was 150 
subsequently dismantled and each stage along with the inhaler device were washed with 151 
appropriate volumes of DI water and collected separately. The collected samples were 152 
freeze dried to remove water. The freeze dried mass was completely dissolved in an 153 
aqueous solution of sodium citrate (0.1M) by magnetic stirring for 4 hours. The solutions 154 
were then analysed for protein content using reverse-phase HPLC (Perkin Elmer, Model 155 
Series 200). The system was equipped with a Gemini C18 column (5m, 250 x 4.6mm, 156 
Phenomenex, UK) and a UV detector (Perkin Elmer, Model Series 200). The following 157 
conditions were used: detection wavelength -220nm; mobile phase A: 0.1%v/v 158 
trifluoroacetic acid (TFA) in water, mobile phase B: 0.08%v/v TFA in acetonitrile; flow rate: 159 
1ml/min[14]. The emitted dose (ED) is the total drug mass exiting the inhaler. The Fine 160 
particle dose (FPD) was calculated as the cumulative amount of drug recovered from Stage 161 
1 to Stage 6 of the device. The fine particle fraction (FPF) is the FPD expressed as a 162 
percentage of ED. The experimental mass median aerodynamic diameter (MMAD) and the 163 
geometric standard deviation (GSD) of the particles were also calculated[15]. All 164 
experiments were carried out in triplicate. 165 
 166 
2.6 In-vitro protein release studies 167 
A Franz diffusion cell was used to carry out in-vitro protein release studies. The apparatus 168 
consists of two chambers, the donor and the receptor, which were separated by a cellulose 169 
acetate (CA) membrane. The receptor chamber of the cell was filled to contain 10ml of pH 170 
7.4 phosphate buffer. 5mg of the microparticles were uniformly deposited on the CA 171 
membrane. 50µl of 0.1M PBS (pH 7.4) with or without porcine pancreatic elastase 172 
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(100g/ml) was added to the donor chamber containing the particles to evaluate elastase-173 
induced degradation of the microparticles and its effect on the release of BSA-FITC. Pure 174 
cross-linked alginate microparticles (without elastin) were also manufactured and subjected 175 
to the same treatment to verify whether alginate had any effect on elastase-mediated 176 
degradation. Specificity of elastin-alginate microparticles to elastase was verified by 177 
exposing them to another serine protease, trypsin at the same concentration (100g/ml). 178 
Samples (250µl) were withdrawn from the receptor compartment at regular time intervals 179 
and analysed spectrophotometrically at 495nm for the content of BSA-FITC. The release 180 
study was also done in the presence of ‘mock’ sputum to determine it’s effect on elastase 181 
activity. 5%w/w gastric mucin was dispersed evenly in DI water[16]. Elastase solution was 182 
mixed with the mucin suspension such that 100l of the suspension contained 5g of 183 
Elastase. This suspension (100l) was evenly spread over the CA membrane. 5mg of 184 
microparticles were then deposited uniformly on the mucin layer.  185 
The release profiles of the untreated and elastase-treated microparticles from all 186 
formulations were compared for similarity using the Fit Factor, f2 described by Moore and 187 
Flanner[17]. This test has also been adopted by the US Food and Drug administration for 188 
comparison of the dissolution profiles of immediate release solid oral dosage forms[18]. In 189 
this test, the average dissolution value from each time point for each formulation is 190 
compared and the overall similarity is calculated. When two release profiles are similar, f2 191 
has a value between 50-100[18]. 192 
2.7 Cytotoxicity studies 193 
Calu-3 cells, an adenocarcinoma cell line derived from a 25 year old Caucasian male were 194 
purchased from the American Type Culture Collection (Rockville, Md., USA) at passage 14 195 
and used between passages 20 and 50.  196 
2.7.1 MTT assay 197 
For viability studies, the cells were plated at a density of 3 x 104/well in a 96-well format at 198 
37°C in 5% CO2. After 24 hours of culture, a suspension containing 1mg of microparticles 199 
per ml of growth media was added to each well and incubated for 24 hours at 37°C and 5% 200 
CO2. Cellular viability was assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-201 
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diphenyltetrazolium bromide) colorimetric assay[19]. Untreated cells were used as controls 202 
and the OD value at 570 nm for untreated cells were considered as 100% viability. 203 
2.7.2 Sodium Fluorescein transport 204 
An in-house developed device was used to impinge the microparticles on to Calu-3 205 
monolayers cultured on Transwell® inserts[20]. To determine the quantity of microparticles 206 
deposited on the cell monolayer, deposition reproducibility studies were conducted for each 207 
formulation. 1mg of spray dried microparticles containing Na-flu were loaded into the 208 
inhaler and aerosolised onto slightly wetted Transwell filter inserts containing no cells (n=5). 209 
The powder deposited on the filters was analysed for the content of Na-flu using a 210 
fluorescence plate reader (Wallac Victor, Perkin Elmer, Cambridge, United Kingdom) at 211 
excitation and emission wavelengths of 488 and 530nm respectively.  212 
After quantifying deposition, blank microparticles of each formulation were aerosolised onto 213 
the cell monolayers. The filter inserts were then placed into new wells containing 1.5ml of 214 
bicarbonated Krebs-Ringer (KRB) solution in the basolateral compartment. 0.5ml of a 50M 215 
Sodium fluorescein (Na-flu) solution in KRB was added to the apical compartment of each 216 
well. 100µl samples were taken at predetermined intervals up to 4hours from the 217 
basolateral compartment and replaced with an equal amount of fresh buffer. The 218 
fluorescence of Na-flu was measured in 96 well plates using a fluorescence plate reader as 219 
above. 220 
2.8 Immunogenicity 221 
Basolateral media collected after 4 hours exposure to the microparticles were analysed for 222 
IL-8 levels using ELISA MAXTM Kit (Biolegend, Inc., San Diego, CA, USA). 223 
2.9 Statistical analysis  224 
Data for each experiment was expressed as mean ± standard deviation. The results were 225 
analysed for statistical significance using unpaired Student's t-test. A probability level of 226 
<0.05 was considered to be statistically significant. 227 
 228 
 229 
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3.0 Results 230 
3.1 Physico-chemical characterisation of microparticles 231 
The geometric diameter of the particles as determined by laser diffraction was 232 
4.12±0.65µm. The tapped density of the particles was 0.09±0.02g/cm3. Using the two data, 233 
the calculated aerodynamic diameter of the particles was 1.24µm. The MMAD of the 234 
particles as determined using the ACI was 3.65±0.26µm with a GSD of 1.84±0.06. SEM 235 
studies showed that alginate-elastin particles had a raisin-like or corrugated morphology 236 
(Figure 1, A to C) possibly due to adsorption of elastin at the air/liquid interface of the 237 
droplets in the spray[21]. Crystals of the crosslinking agent, CaCl2 were also seen 238 
embedded to the surface of these particles.  239 
The encapsulation efficiency of BSA-FITC in the particles was 96.8±5.7%. Aerosolisation 240 
studies using the ACI showed the fine particle fraction of the microparticles to be 241 
31.3±7.5%. The quantity of protein deposited at each stage of the impactor is shown in 242 
Figure 2, expressed as % of the loading dose. 243 
3.2 Bioresponsive protein release in-vitro 244 
Protein release studies for alginate-elastin particles were carried out using Franz diffusion 245 
cells in the presence and absence of elastase. The concentration of elastase used for the 246 
studies was within the reported range for sputum samples from infected bronchitic and 247 
cystic fibrosis patients, which is 26-100µg/ml[22]. Complete release of BSA-FITC was seen 248 
with the alginate-elastin microparticles that were exposed to elastase while less than 10% 249 
of the protein was released with the controls i.e. non-elastase exposed particles (Figure 250 
3A). The two release profiles were compared for similarity using the Fit factor (f2) model. 251 
The value of f2 was 15.6 indicating a significant difference between the 2 release profiles. 252 
Trypsin had no effect on the rate of degradation of the microparticles with the level of 253 
protein release being similar to the untreated controls (Figure 3A). Cross-linked alginate 254 
particles (without elastin) that were treated with elastase also showed a protein release 255 
profile that was similar to the controls. 256 
Elastase treated alginate-elastin particles showed similar drug release profiles in the 257 
presence and absence of ‘mock’ sputum indicating that sputum had no effect on elastase 258 
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activity (Figure 3B).Comparing the two release profiles using the Fit factor model gave a 259 
value of 78.7 for f2. In the presence of mock sputum, alginate-elastin microparticles that 260 
were exposed to elastase showed significantly higher release of BSA-FITC as compared to 261 
the control samples (not exposed to elastase) (Figure 3B). Using the Fit factor model gave 262 
a value of 18.9 for f2 indicating a significant difference between the two release profiles. 263 
3.3 Cytotoxicity and immunogenicity 264 
With the MTT assay, after 24 hours exposure to the microparticles, no significant difference 265 
(p<0.05) in viability was observed between the treated cells and the control (Table 1). 266 
Deposition reproducibility studies using blank filters (without cells) showed that, of the 1mg 267 
of microparticles that were initially loaded in the inhaler, 564±122g was reproducibly 268 
delivered on to each insert using the in-house device. The apparent permeability coefficient 269 
(Papp) of Sodium Fluorescein for cell monolayers that were impinged with the microparticles 270 
was similar to the control (p<0.05) (Table 1) and no permeation enhancement effects were 271 
therefore evident. Basolateral media collected after 4 hours exposure to the microparticles 272 
was analyzed for the inflammatory marker, Interleukin (IL) -8. No significant increase in the 273 
level of secretion was observed (p < 0.05) (Table 1). 274 
 275 
4.0 Discussion 276 
While site-specific drug delivery after oral administration of drugs using polymers 277 
has become common-place e.g. enteric coated tablets, little work has been done to-date on 278 
harnessing polymeric carriers for site-specific delivery in the lungs after inhalation. Given 279 
that airway inflammation in asthma and COPD is associated with high levels of active 280 
neutrophil elastase[6], polymeric carriers that undergo degradation in the presence of this 281 
enzyme could be used to achieve targeted delivery of anti-inflammatory drugs to the lungs. 282 
Spray drying was used in this study as a one-step process to produce microparticles 283 
of inhalable size. To stabilise the particles, an ionic crosslinking based approach was 284 
explored. This involved combining a specific elastase substrate, elastin with a 285 
polysaccharide, alginate. Conventionally used chemical crosslinking agents (eg. aldehydes) 286 
during particle preparation are considered toxic[23]. An alternative approach was 287 
harnessed in this study. Crosslinking of alginate was achieved using Ca+2 ions to produce a 288 
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matrix in which elastin molecules were interwoven with crosslinked molecules of alginate. 289 
With this technique, the integrity of the individual polymers was maintained as no covalent 290 
modification was required.  CaCl2 is currently used in a marketed inhalable formulation of 291 
rhDNase, Pulmozyme® with patients inhaling upto 0.8mg of the salt per day[24]. For the 292 
present study, assuming a daily dose of 40mg of the powder and an inhaler delivery 293 
efficiency of 30-40%, 12-16mg of the formulation is emitted from the device[25]. About 40% 294 
of the emitted dose is considered to deposit in the central and intermediate lung (i. e. 4.8-295 
6.4mg)[26]. The quantity of CaCl2 from this dose works out to be 1.2-1.5mg which is close 296 
to the marketed formulation. IPNs also have advantages for enzyme targeted drug delivery 297 
systems (DDS) as it is possible to control the rate and extent of enzymatic degradation of 298 
the DDS by varying the proportion of the enzyme sensitive polymer within the IPN 299 
network[27]. In vitro protein release studies showed low non-specific release of BSA-FITC 300 
(7%) from the particles over a period of 4 hours. On contact with the small volume of 301 
release media present on the apical side of the franz cells (at 37°C), soluble elastin 302 
possibly undergoes reversible coacervation to form a mucilaginous precipitate[28]. An 303 
insoluble calcium alginate gel layer would also form due to dissolution of the crystals of 304 
CaCl2 as they come in contact with the dissolution medium. This combined viscous gel 305 
barrier inhibits penetration of the dissolution medium into the particle matrix thereby 306 
reducing non-specific release of BSA-FITC from the microparticles. On treatment of 307 
alginate-elastin microparticles with elastase, complete release of BSA-FITC was observed 308 
within 4 hours. Elastin is rich in hydrophobic amino acids such as alanine, valine, proline 309 
and glycine that form a large number of elastase-cleavable sites within the protein[29]. Ca+2 310 
ions in this study were used to crosslink alginate while no crosslinking agent was used for 311 
elastin. And yet, a dramatic increase in the release of BSA-FITC was observed when the 312 
particles were exposed to elastase. This suggested that elastin was important in 313 
maintaining the integrity of the particles and preventing non-specific protein release. In 314 
studies conducted on enzyme degradable IPNs consisting of  gelatin and dextran, 315 
Kurisawa et al. reported the presence of intimate physical chain entanglements between 316 
the two polymers[8].  Among proteins, elastin is unique in that it can self-assemble at 37ºC 317 
via interactions between its hydrophobic amino acids to form cross-links in-situ[9]. This 318 
coacervation process could also be promoted via ionic interactions between the lysine 319 
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residues of elastin and the carboxylate moieties in alginate[30]. Thus even in the absence 320 
of an external crosslinking agent, elastin could have reinforced the network through the 321 
combined effect of self-association and inter-polymer chain entanglement. Elastase had no 322 
effect on protein release from crosslinked alginate microparticles that did not contain 323 
elastin. To determine whether alginate-elastin microparticles would undergo degradation by 324 
other enzymes, the microparticles were exposed to another protease, trypsin. Trypsin had 325 
no effect on the release of BSA-FITC from the particles with the release profile being 326 
similar to the controls (untreated microparticles). Trypsin cleaves mainly at sites that 327 
contain positively charged amino acids such as arginine or lysine[31]. These amino acids 328 
are present in very low amounts in elastin[32]. 329 
Mucus accumulation in the airways is a characteristic feature of lung diseases such 330 
as cystic fibrosis. Particles carrying drugs to treat such conditions are likely to deposit on 331 
lung mucus and interact with its components. For example, interaction of alginate with the 332 
glycoproteins present in mucus (mucins) has been reported to induce the formation of a 333 
viscoelastic gel[33]. Such a gel formation could inhibit elastase-mediated degradation of the 334 
particles. To evaluate this, hydrated gastric mucin, which consists of high molecular weight 335 
glycoproteins from the porcine stomach, was used as a model to study possible effects of 336 
alginate-mucin interaction on elastase-mediated protein release[16]. As shown in Figure 337 
2B, the presence of mucin had no impact on the rate and extent of elastase mediated 338 
degradation of the particles. However, in the absence of elastase, the mucin caused about 339 
24% BSA-FITC to be released from the microparticles non-specifically. Without sputum, 340 
non-specific release had been low at 7%. During the release study, the presence of a 341 
hydrated mucin layer (sputum) on the surface of the filter membrane meant that these 342 
microparticles were wetted to a greater extent than the particles that were deposited on the 343 
membrane alone (without sputum). This increased wetting and consequent dissolution or 344 
erosion of the polymeric network could be responsible for the higher non-specific protein 345 
release observed with the alginate-elastin microparticles in the presence of the sputum. 346 
Interactions between uncharged particles occurs mainly via Van der Waals (VDW) forces. 347 
These are attractive forces that arise due to the formation of dipoles in a molecule. The 348 
magnitude of the VDW forces (F) between two ideally smooth spheres of diameters d1 and 349 
d2, separated by a distance r in vacuum is given by the following relation[34], 350 
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F = (A / 12r2) x (d1d2) / (d1 + d2) 351 
where A is a constant.  352 
As seen from the above relation, interparticulate forces decrease as a function of increased 353 
distance of separation between the particles and hence, any means of increasing this 354 
distance would reduce particulate interaction. Particles having small surface protrusions 355 
experience reduced VDW attractive forces since the protrusions increase the separation 356 
distance between the particles.  357 
Alginate-elastin particles had a highly corrugated surface morphology with prominent 358 
grooves and ridges. Crystals of CaCl2 also protruded outwards from their surface. These 359 
factors would have increased the distance of separation between the particles thereby 360 
reducing cohesive VDW forces. This would explain the high dispersability and respirable 361 
fraction observed with these particles.  362 
5.0 Conclusion 363 
The use of an IPN as an enzyme targeted drug delivery system for the inhaled route has 364 
not been reported before. In this study, we have shown that IPNs can be readily 365 
manufactured by spray drying into inhalable microparticles, a method that is easily scaled-366 
up. The particles provided controlled and enzyme-specific drug release and were easily 367 
aerosolised. Even though in vitro assays did not reveal any particle induced cytotoxic or 368 
immunogenic effects, other factors such as the accumulation of these polymeric carriers 369 
within the lungs on prolonged administration must be considered. 370 
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 454 
Table legends: 455 
 456 
Table 1: Effect of exposure of Calu-3 cells to Alginate-elastin microparticles with 457 
respect to cellular viability, apparent permeability (Papp) of Sodium-fluorescein and 458 
secretion of IL-8 (n=4SD) 459 
 460 
Figure legends: 461 
 462 
Figure 1: Scanning electron micrographs of BSA loaded alginate-elastin 463 
microparticles: (A) at 30,000X magnification; (B) and (C) at 80,000X magnification  464 
 465 
Figure 2: The deposition of BSA-FITC loaded microparticles in different stages of an 466 
Andersen cascade impactor operated at 60 l/min (n=3±SD). 467 
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 468 
Figure 3A: BSA-FITC release profiles from alginate-elastin microparticles treated 469 
with/without elastase or with trypsin (n=3SD). 470 
Figure 3B: BSA-FITC release profiles from untreated or elastase treated alginate-471 
elastin microparticles in the presence and absence of ‘mock’ sputum (n=3SD). 472 
 473 
Table 1:  474 
Treatment 
Papp (x 10-7cm/sec)  
of Fluorescein Sodium 
% cell viability 
IL-8 
(pg/ml) 
Control 1.07±0.11 100±7.6 219±28 
Alginate-elastin microparticles 0.67±0.14 111.2±6.7 231±66 
 475 
 476 
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Figure 2477 
 478 
